Literature DB >> 10857837

Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup.

S Bonini1, S Bonini1, A Lambiase, S Marchi, P Pasqualetti, O Zuccaro, P Rama, L Magrini, T Juhas, M G Bucci.   

Abstract

OBJECTIVE: This study aimed at revisiting vernal keratoconjunctivitis (VKC) on the basis of anamnestic, clinical, immunologic, histopathologic, and followup data of 195 patients.
DESIGN: Retrospective noncomparative case series. PARTICIPANTS: One hundred and ninety-five patients with VKC.
METHODS: Clinical evaluation and outcome in 151 of 195 patients with a median followup of 47 months. Evaluation was by telephone survey in 69 patients. MAIN OUTCOME MEASURES: (1) Demographic, clinical, and immunologic features of VKC and their influence on the course of the disease; (2) conjunctival and corneal complications and efficacy of treatment observed during the followup period.
RESULTS: VKC is a chronic disease. More than 60% of patients had repeated recurrences all year round. Males had an earlier presentation of symptoms than females and the male/female ratio decreased with age. Major (greater than 80%) and minor (up to 80%) diagnostic criteria were defined for clinical signs and symptoms of the disease. Negative skin test or radioallergosorbent test was present in approximately 50% of patients, whereas eosinophil infiltration was a constant histopathologic finding. A marked conjunctival sensitivity to nonspecific stimuli was noted in more than one third of patients. In 6% of cases, a reduction of visual acuity resulted from corneal scarring, and in 2% of patients, steroid-induced glaucoma was observed. The large size of giant papillae indicates poor prognosis for the persistence of the disease and its evolution into a chronic, perennial condition.
CONCLUSIONS: VKC is a chronic eosinophilic disease of the ocular surface involving IgE, non IgE-mediated mechanisms, and age-sex-related influences. Although the disease has a good prognosis, severe visual impairments may result from long-standing inflammation.

Entities:  

Mesh:

Year:  2000        PMID: 10857837     DOI: 10.1016/s0161-6420(00)00092-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  62 in total

1.  Vernal keratoconjunctivitis in school children in Rwanda and its association with socio-economic status: a population-based survey.

Authors:  Stefan De Smedt; John Nkurikiye; Yannick Fonteyne; Arjan Hogewoning; Marjan Van Esbroeck; Dirk De Bacquer; Stephen Tuft; Clare Gilbert; Joris Delanghe; Philippe Kestelyn
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

2.  Corneal biochemical features of patients with vernal keratoconjunctivitis.

Authors:  Sinan Emre; Esin Başer; Bilge Oztürk; Sibel Zorlu; Ozgür Uzun; Ceren Gülhan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-22       Impact factor: 3.117

Review 3.  Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis.

Authors:  F Mantelli; M S Santos; T Petitti; R Sgrulletta; M Cortes; A Lambiase; S Bonini
Journal:  Br J Ophthalmol       Date:  2007-06-22       Impact factor: 4.638

4.  Vernal keratoconjunctivitis.

Authors:  Anthony Hall; Bernadetha Shilio
Journal:  Community Eye Health       Date:  2005-03

5.  Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.

Authors:  Veysi Oner; Fatih Mehmet Türkcü; Mehmet Taş; Mehmet Fuat Alakuş; Yalçın Işcan
Journal:  Jpn J Ophthalmol       Date:  2012-05-25       Impact factor: 2.447

6.  Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis.

Authors:  Gennaro D'Angelo; Alessandro Lambiase; Magdalena Cortes; Roberto Sgrulletta; Roberta Pasqualetti; Ambra Lamagna; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-15       Impact factor: 3.117

7.  Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children.

Authors:  Ugur Keklikci; Sevda I Soker; Yildirim B Sakalar; Kaan Unlu; Selver Ozekinci; Selcuk Tunik
Journal:  Jpn J Ophthalmol       Date:  2008-11-11       Impact factor: 2.447

8.  Alpha-1 antitrypsin, a diagnostic and prognostic marker of vernal keratoconjunctivitis.

Authors:  Akif Ahsan; Khushtar A Salman; Sana Alam; Anwar H Siddiqui; Syed Shariq Naeem; Aquil Ahmad; Iqbal M Khan
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 9.  An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.

Authors:  Susanna Esposito; Giulia Fior; Alessandro Mori; Silvia Osnaghi; Daniele Ghiglioni
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

10.  Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva.

Authors:  Alessandra Micera; Alessandro Lambiase; Barbara Stampachiacchiere; Roberto Sgrulletta; Eduardo Maria Normando; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2007-06-21       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.